P. Souverein

First name
P.
Middle name
C.
Last name
Souverein
Rasmussen, N. H., Driessen, J. H. M., Kvist, A. V., Souverein, P. C., van den Bergh, J. P., & Vestergaard, P. (2023). Fracture patterns and associated risk factors in pediatric and early adulthood type 1 diabetes: Findings from a nationwide retrospective cohort study. Bone, 180, 116997. http://doi.org/10.1016/j.bone.2023.116997
Schene, M. R., Wyers, C. E., Driessen, A. M. H., Souverein, P. C., Gemmeke, M., van den Bergh, J. P., & Willems, H. C. (2023). Imminent fall risk after fracture. Age Ageing, 52. http://doi.org/10.1093/ageing/afad201
van Hulten, V., Driessen, J. H. M., Starup-Linde, J. K., Al-Mashhadi, Z. K., Viggers, R., Klungel, O. H., et al. (2023). The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus. Diabetes Obes Metab. http://doi.org/10.1111/dom.15220
Gulikers, J. L., van Veelen, A. J., Driessen, J. H. M., Souverein, P. C., Tjan-Heijnen, V. C. G., Hendriks, L. E. L., et al. (2023). Comparison of characteristics of patients with lung cancer in U.K. primary care databases: Clinical Practice Research Datalink Aurum and GOLD. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.5637
Hageman, S. H., Petitjean, C., Pennells, L., Kaptoge, S., Pajouheshnia, R., Tillmann, T., et al. (2023). Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2. Eur J Prev Cardiol. http://doi.org/10.1093/eurjpc/zwad187
Hunt, N. B., Pajouheshnia, R., Salih, A., van Doorn, S., Souverein, P. C., Bazelier, M. T., et al. (2023). Prescribing of Low-dose Rivaroxaban in Patients with Atherosclerotic Cardiovascular Disease in the United Kingdom and the Netherlands. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.15708
Sarodnik, C., Rasmussen, N. H., Bours, S. P. G., Schaper, N. C., Vestergaard, P., Souverein, P. C., et al. (2022). The incidence of fractures at various sites in newly treated patients with type 2 diabetes mellitus. Bone Rep, 17, 101614. http://doi.org/10.1016/j.bonr.2022.101614
Eroglu, T. E., Coronel, R., Zuurbier, C. J., Blom, M., de Boer, A., & Souverein, P. C. (2022). Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus. Eur Heart J Cardiovasc Pharmacother. http://doi.org/10.1093/ehjcvp/pvac043
Leung, M. W., Bazelier, M. T., Souverein, P. C., Uitdehaag, B. M., Klungel, O. H., Leufkens, H. G., & Pajouheshnia, R. (2022). Mapping the risk of infections in patients with multiple sclerosis: A multi-database study in the United Kingdom Clinical Practice Research Datalink GOLD and Aurum. Mult Scler, 13524585221094218. http://doi.org/10.1177/13524585221094218
van Sloten, T. T., Souverein, P. C., Stehouwer, C. D., & Driessen, J. H. (2022). Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and risk of depression among older people with hypertension. J Psychopharmacol, 2698811221082470. http://doi.org/10.1177/02698811221082470